Information Provided By: 
Fly News Breaks for May 13, 2016
MYL
May 13, 2016 | 06:24 EDT
Goldman analyst Jami Rubin removed Mylan (MYL) from the Conviction Buy List and maintained his Buy rating and $60 price target. The analyst believes the cloud over generic drug pricing may persist longer than expected and sees greater catalysts near-term from Allergan (AGN), which was added to the Conviction Buy List.
News For MYL From the Last 2 Days
There are no results for your query MYL
